{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:33:24Z","timestamp":1761863604275},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The use of direct acting agents has changed the management paradigm of hepatitis C (HCV) in liver transplant (LT) recipients. However, the appropriate antiviral regimen in LT recipients on hemodialysis (HD) remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively evaluated the safety and efficacy of sofosbuvir-based LT recipients on HD followed at the University of California Los Angeles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twelve LT recipients on HD were treated for recurrent HCV with sofosbuvir-based therapy. Indications for antiviral therapy included fibrosing cholestatic hepatitis, symptomatic cryoglobulinemia, and recurrent HCV. The causes of renal failure included hepatorenal syndrome, acute tubular necrosis and cryoglobulinemia. Of those who were not on dialysis at the time of transplantation, the mean creatinine (\u00b1SD) was 1.7 (\u00b10.8) mg\/dL. The mean age (\u00b1SD) of the cohort was 62.2 (\u00b16.0) years. Most recipients were male (67%) and infected with genotype 1 (83%). Baseline alanine aminotransferase, total bilirubin, hemoglobin and HCV RNA values (\u00b1SD) were 53.2 (\u00b159.4) IU\/L, 3.2 (\u00b15.5) mg\/dL, 10.5 (\u00b11.8) g\/dL, and 30,499,500 (\u00b129,655,754) IU\/mL. HCV RNA levels were undetectable in all recipients at the end of therapy. The trough mean (\u00b1SD) hemoglobin of patients on treatment and on HD was 8.4 (\u00b12.3). The sustained viral response was 58% (7\/12), and the overall patient survival was 42%. All the deaths occurred a mean (\u00b1SD) after 5.4 (\u00b13.6) months after treatment was completed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>All patients achieved viral suppression from therapy, and over half the recipients achieved a sustained virological response. A high mortality underscores the necessity of starting antiviral treatment sooner in LT recipients and the need for larger cohort studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcg.0000000000000640","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T20:35:05Z","timestamp":1471638905000},"page":"167-173","source":"Crossref","is-referenced-by-count":9,"title":["Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis"],"prefix":"10.1097","volume":"51","author":[{"given":"Sammy","family":"Saab","sequence":"first","affiliation":[{"name":"Surgery"},{"name":"Medicine, University of California at Los Angeles, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"A. Jimenez","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherona","family":"N. Bau","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Choi","sequence":"additional","affiliation":[{"name":"Surgery"},{"name":"Medicine, University of California at Los Angeles, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco A.","family":"Durazo","sequence":"additional","affiliation":[{"name":"Surgery"},{"name":"Medicine, University of California at Los Angeles, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"M. El-Kabany","sequence":"additional","affiliation":[{"name":"Surgery"},{"name":"Medicine, University of California at Los Angeles, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven-Huy B.","family":"Han","sequence":"additional","affiliation":[{"name":"Surgery"},{"name":"Medicine, University of California at Los Angeles, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald W.","family":"Busuttil","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230913","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"R2-20230913","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.28422","article-title":"Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)","volume":"64","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis","volume":"62","author":"Reddy","year":"2015","journal-title":"Hepatology"},{"key":"R8-20230913","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/hep.28425","article-title":"Safety and efficacy of ledipasvir\/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older","volume":"63","author":"Saab","year":"2015","journal-title":"Hepatology"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hep.27890","article-title":"Safety and tolerability of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials","volume":"62","author":"Alqahtani","year":"2015","journal-title":"Hepatology"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/ctr.12584","article-title":"Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis","volume":"29","author":"Saab","year":"2015","journal-title":"Clin Transplant"},{"key":"R11-20230913","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/liv.12856","article-title":"Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients","volume":"35","author":"Saab","year":"2015","journal-title":"Liver Int"},{"key":"R12-20230913","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hep.28334","article-title":"Safety and efficacy of ledipasvir-sofosbuvir in African Americans with hepatitis C virus infection: a retrospective analysis of phase 3 data","volume":"63","author":"Wilder","year":"2015","journal-title":"Hepatology"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-20230913","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"548","DOI":"10.4254\/wjh.v7.i3.548","article-title":"Hepatitis C in hemodialysis patients","volume":"7","author":"Marinaki","year":"2015","journal-title":"World J Hepatol"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"S670","DOI":"10.1016\/S0168-8278(15)31080-1","article-title":"First ribavinin-free sofosbuvir and simeprevir treatment of hepatitis C genotype 1 patients with severe renal impairment (GFR <30 mL\/min or dialysis) (Abstract)","volume":"62","author":"Czul","year":"2015","journal-title":"J Hepatol"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and Simeprevir in Hepatitis C genotype 1- patients with end-stage renal disease on hemodialysis or GFR <30 mL\/min","volume":"36","author":"Nazario","year":"2015","journal-title":"Liver Int"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10620-015-3756-z","article-title":"A new standard of care? Standard dose sofosbuvir in an HCV-infected liver transplant recipient undergoing hemodialysis","volume":"61","author":"Perumpail","year":"2016","journal-title":"Dig Dis Sci"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/tid.12348","article-title":"Sofosbuvir and Simeprevir combination therapy in the setting of liver transplantation and hemodialysis","volume":"17","author":"Perumpail","year":"2015","journal-title":"Transplant Infect Dis"},{"key":"R25-20230913","doi-asserted-by":"crossref","first-page":"561","DOI":"10.12659\/AOT.893640","article-title":"Interferon-free Sofosbuvir-based anti-HCV therapy after liver transplantation","volume":"20","author":"Seifert","year":"2015","journal-title":"Ann Transplant"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1681\/ASN.2013040436","article-title":"Patient-specific prediction of ESRD after liver transplantation","volume":"24","author":"Sharma","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R28-20230913","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.transproceed.2013.11.124","article-title":"Renal dysfunction after orthotopic liver transplantation","volume":"46","author":"Sirivatanauksorn","year":"2014","journal-title":"Transplant Proc"},{"key":"R29-20230913","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/lt.23522","article-title":"Renal dysfunction in liver transplant recipients: evaluation of the critical issues","volume":"18","author":"Weber","year":"2012","journal-title":"Liver Transpl"},{"key":"R30-20230913","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDL long-term follow-up study","volume":"10","author":"Watt","year":"2010","journal-title":"AM J Transplant"},{"key":"R31-20230913","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.21821","article-title":"Renal outcomesafter liver transplantation in the model for end-stage liver disease era","volume":"15","author":"Sharma","year":"2009","journal-title":"Liver Transpl"},{"key":"R32-20230913","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/apt.13027","article-title":"The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-20230913","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.27538","article-title":"Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study","volume":"61","author":"\u00c5berg","year":"2015","journal-title":"Hepatology"},{"key":"R34-20230913","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/lt.21011","article-title":"Early histological changes in fibrosing cholestatic hepatitis C","volume":"13","author":"Dixon","year":"2007","journal-title":"Liver Transpl"},{"key":"R35-20230913","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transpl"},{"key":"R36-20230913","first-page":"185","article-title":"Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation","volume":"6","author":"Abrahamian","year":"2000","journal-title":"Liver Transpl"},{"key":"R37-20230913","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.23756","article-title":"Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease","volume":"20","author":"Bl\u00e9","year":"2014","journal-title":"Liver Transpl"},{"key":"R38-20230913","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.cgh.2015.05.030","article-title":"Efficacy of Sofosbuvir and Daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation","volume":"13","author":"Leroy","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R39-20230913","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14218\/JCTH.2016.00001","article-title":"Curing hepatitis C in liver transplant recipients is associated with changes in immunosuppressant use","volume":"4","author":"Saab","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"R40-20230913","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOT.0000000000000198","article-title":"New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease","volume":"20","author":"Kwo","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"R41-20230913","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s10620-014-3422-x","article-title":"Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis","volume":"60","author":"Stine","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R42-20230913","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3851\/IMP2969","article-title":"Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis","volume":"21","author":"Soriano","year":"2015","journal-title":"Antivir Ther"},{"key":"R43-20230913","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"R44-20230913","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"RUBY-I: Ombitasvir\/Paritaprevir\/Ritonavir+Dasabuvir +\/\u2212 Ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"R45-20230913","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"key":"R46-20230913","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1053\/j.gastro.2015.09.031","article-title":"Interaction between Amiodarone and Sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned","volume":"149","author":"Back","year":"2015","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004836-201702000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:17:11Z","timestamp":1694639831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201702000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000000640","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}